NCT01629732View on ClinicalTrials.gov

Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

June 30, 2014

Conditions
Hepatitis C Virus
Interventions
DRUG

Daclatasvir

Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks

DRUG

Daclatasvir

Film coated tablet, Oral, 60 mg, Once daily, 24 weeks

DRUG

BMS-986094

Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks

DRUG

BMS-986094

Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks

DRUG

BMS-986094

Capsule, Oral, 200 mg, Once daily, 24 Weeks

DRUG

Ribavirin

Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks

DRUG

Placebo for BMS-986094

Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks

Trial Locations (1)

32804

Local Institution, Orlando

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY